Literature DB >> 26985447

Significance of Proline Residue on Short Mucin Peptide Interactions with Mouse MUC1 Monoclonal Antibody Studied by Saturation Transfer Difference NMR Spectroscopy.

Cheng Her1, William M Westler2, Thao Yang1.   

Abstract

In this study we investigated to see whether or not a shortened MUC1 mucin peptide epitope with the sequence GVTSAPD containing a single prolyl residue would still bind specific monoclonal antibody as its native sequence (e.g., PDTRP), known to be the specific recognition site on the Variable Number Tandem Repeat (VNTR) region of MUC1 mucin by the immune system. The affinity of GVTSAPD peptide to a mouse Muc1 mucin specific monoclonal antibody (clone 6A4, IgG1 isotype) was investigated by Saturation Transfer Difference NMR spectroscopy (STD NMR). Results showed that the shortened mucin epitope GVTSAPD still retained affinity to Muc1 specific monoclonal antibody (mAb) while one that lacks the prolyl residue at position 6 lost its affinity, which suggests that P6 is necessay for antibody binding. The interactions observed by STD NMR occurred strongest at the P6 side chain 1H's (βH and γH); the P6Hα showed lower degree of saturation transfer effect. Minor interactions also occurred at the methyl groups of V2' T3 and A5. Mucin peptides derived from the VNTR region have been the target of cancer vaccine research, thus properties associated with mucin peptide structure, conformation and antibody interaction are central to peptide design or engineering towards that end.

Entities:  

Keywords:  MUC1 antibody recognition epitope; Mucin peptide; Saturation Transfer Difference NMR Spectroscopy (STD NMR)

Year:  2013        PMID: 26985447      PMCID: PMC4791070     

Source DB:  PubMed          Journal:  JSM Chem        ISSN: 2334-1831


  33 in total

1.  Involvement of the MAP kinase ERK2 in MUC1 mucin signaling.

Authors:  D Meerzaman; P S Shapiro; K C Kim
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-07       Impact factor: 5.464

2.  MUC1 expression in hemopoietic tissues.

Authors:  W Krüger; N Kröger; A R Zander
Journal:  J Hematother Stem Cell Res       Date:  2000-08

3.  Synthesis of MUC1-lipopeptide chimeras.

Authors:  Brendan L Wilkinson; Lara R Malins; Candy K Y Chun; Richard J Payne
Journal:  Chem Commun (Camb)       Date:  2010-07-28       Impact factor: 6.222

4.  Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2.

Authors:  Anton Kaiser; Nikola Gaidzik; Torsten Becker; Clara Menge; Kai Groh; Hui Cai; Yan-Mei Li; Bastian Gerlitzki; Edgar Schmitt; Horst Kunz
Journal:  Angew Chem Int Ed Engl       Date:  2010-05-10       Impact factor: 15.336

5.  Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor.

Authors:  M Mayer; B Meyer
Journal:  J Am Chem Soc       Date:  2001-06-27       Impact factor: 15.419

6.  1H-NMR studies on a potent and selective antagonist at human melanocortin receptor 4 (hMC-4R).

Authors:  Maria Victoria Silva Elipe; Ralph T Mosley; Maria A Bednarek; Byron H Arison
Journal:  Biopolymers       Date:  2003-04       Impact factor: 2.505

7.  Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide-antibody interactions.

Authors:  Jeffrey S Grinstead; R Rao Koganty; Mark J Krantz; B Michael Longenecker; A Patricia Campbell
Journal:  Biochemistry       Date:  2002-08-06       Impact factor: 3.162

8.  Competition STD NMR for the detection of high-affinity ligands and NMR-based screening.

Authors:  Yu-Sen Wang; Dingjiang Liu; Daniel F Wyss
Journal:  Magn Reson Chem       Date:  2004-06       Impact factor: 2.447

9.  MUC1 initiates a calcium signal after ligation by intercellular adhesion molecule-1.

Authors:  Jennifer J Rahn; Qiang Shen; Brian K Mah; Judith C Hugh
Journal:  J Biol Chem       Date:  2004-05-28       Impact factor: 5.157

Review 10.  MUC1, the renaissance molecule.

Authors:  S J Gendler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.